Skip to content

Regulatory Crackdown: FDA Targets Hims and Similar Online Health Platforms in Intensive Drug Advertisement Campaign

Health Officals Crackdown on Telehealth Firms: Authorities in the U.S. are taking action against telehealth companies that peddle unauthorized versions of prescription drugs, including weight loss medications. Notable companies like Hims & Hers have received warnings to eliminate misleading...

Federal regulatory body, the FDA, launches a campaign targeting telehealth services such as Hims,...
Federal regulatory body, the FDA, launches a campaign targeting telehealth services such as Hims, focusing on the regulation of drug advertising practices

Regulatory Crackdown: FDA Targets Hims and Similar Online Health Platforms in Intensive Drug Advertisement Campaign

In a significant move, the Food and Drug Administration (FDA) has issued warnings to telehealth company Hims & Hers to remove 'false and misleading' promotional statements from its website. The crackdown is part of the Trump administration's efforts to regulate pharmaceutical advertising.

The FDA specifically warned Hims & Hers about language claiming that its customized products contain 'the same active ingredient' as FDA-approved drugs Wegovy and Ozempic. The formulations cited by regulators are produced by specialty compounding pharmacies and aren't reviewed by the FDA.

Hims & Hers has built a multibillion-dollar business centered around lower-cost versions of blockbuster obesity injections. The company partnered with one of the largest generic drug manufacturers in the US to produce their compounded versions of Wegovy and Ozempic, but the specific name of the specialty pharmacy or manufacturer remains undisclosed. This partnership aims to ensure consistent supply for their products.

As part of the FDA's action, more than 100 letters were posted, targeting various drug and online prescribing companies, including Hims & Hers. The incident underscores the FDA's commitment to protecting consumers from potentially dangerous and unapproved drugs.

We invite our esteemed audience of approximately 2 million industry professionals to subscribe to our newsletter for regular updates and insights on this developing story and other relevant news. By subscribing, you'll receive the newsletter directly in your inbox.

In addition, we are excited to announce the launch of our mobile application. This innovative tool offers real-time updates and the ability to save your favourite articles, keeping you informed and engaged with the latest industry news.

Stay tuned for more updates as we continue to bring you the most accurate and up-to-date information on this story and many more.

Read also:

Latest